| Name | Title | Contact Details |
|---|
Aileron Therapeutics, based in Cambridge, Massachusetts, is a biopharmaceutical company developing and advancing a revolutionary class of drugs called Stapled Peptides. The company`s proprietary Stapled Peptides platform is a breakthrough approach to creating drugs for highly sought after biological targets using its novel peptide stabilizing technologies.
Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases.
Hays Life Sciences is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Spruce is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Our wholly-owned product candidate, tildacerfont, is a CRF1 receptor antagonist currently in late-stage trials in adult patients with classic congenital adrenal hyperplasia (CAH), with a planned Phase 2 trial in pediatric classic CAH. We aim to advance the treatment paradigm for classic CAH with a well-tolerated, non-steroidal approach designed to offer markedly improved disease control and reduced steroid burden for patients. Tildacerfont may also benefit patients with other disorders characterized by elevated levels of or hyperresponsiveness to adrenocorticotropic hormone (ACTH), a hormone involved in the production of cortisol, including a rare form of polycystic ovary syndrome (PCOS).
Canadian Bacterial Diseases Network (CBDN) is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.